AU2003260489A1 - Treatment of neurological disorders by dsrna adminitration - Google Patents

Treatment of neurological disorders by dsrna adminitration

Info

Publication number
AU2003260489A1
AU2003260489A1 AU2003260489A AU2003260489A AU2003260489A1 AU 2003260489 A1 AU2003260489 A1 AU 2003260489A1 AU 2003260489 A AU2003260489 A AU 2003260489A AU 2003260489 A AU2003260489 A AU 2003260489A AU 2003260489 A1 AU2003260489 A1 AU 2003260489A1
Authority
AU
Australia
Prior art keywords
adminitration
dsrna
treatment
neurological disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003260489A
Other languages
English (en)
Inventor
Gabriele Dorn
Pamposh Ganju
Jonathan Hall
Maria Wanda Hemmings
Wiliam Leonard Wishart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003260489A1 publication Critical patent/AU2003260489A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003260489A 2002-09-04 2003-09-03 Treatment of neurological disorders by dsrna adminitration Abandoned AU2003260489A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40800002P 2002-09-04 2002-09-04
US60/408,000 2002-09-04
US45797103P 2003-03-27 2003-03-27
US60/457,971 2003-03-27
PCT/EP2003/009787 WO2004022075A1 (en) 2002-09-04 2003-09-03 Treatment of neurological disorders by dsrna adminitration

Publications (1)

Publication Number Publication Date
AU2003260489A1 true AU2003260489A1 (en) 2004-03-29

Family

ID=31981555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003260489A Abandoned AU2003260489A1 (en) 2002-09-04 2003-09-03 Treatment of neurological disorders by dsrna adminitration

Country Status (5)

Country Link
US (3) US20060030534A1 (https=)
EP (1) EP1551424B1 (https=)
JP (2) JP4754216B2 (https=)
AU (1) AU2003260489A1 (https=)
WO (1) WO2004022075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
EP1407787B1 (en) * 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Method of promoting nucleic acid transfer
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
MX2007002423A (es) * 2004-08-31 2007-08-07 Sylentis Sau Metodos y composiciones para inhibir la expresion del receptor p2x7.
AR051829A1 (es) * 2004-10-27 2007-02-14 Schering Corp Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia
WO2007020935A1 (ja) * 2005-08-17 2007-02-22 Ono Pharmaceutical Co., Ltd. Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
RU2607033C2 (ru) * 2010-09-28 2017-01-10 Ноно Инк. Пептиды nd2 и способы лечения неврологического заболевания
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
US12128062B2 (en) 2018-08-14 2024-10-29 University Of Maryland, Baltimore Methods for targeting pain directed at metabolic pathways

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
US5155689A (en) * 1991-01-17 1992-10-13 By-Word Technologies, Inc. Vehicle locating and communicating method and apparatus
US5214281A (en) * 1992-03-20 1993-05-25 Rowe Douglas J Method for locating sub-terranean geological aggregate deposits
US5724243A (en) * 1995-02-10 1998-03-03 Highwaymaster Communications, Inc. Method and apparatus for determining expected time of arrival
US5721207A (en) * 1995-04-18 1998-02-24 Innapharma, Inc. Method for treatment of pain
JP3371605B2 (ja) * 1995-04-19 2003-01-27 日産自動車株式会社 大気効果表示機能付き鳥瞰図表示ナビゲーションシステム
US5751450A (en) * 1996-05-22 1998-05-12 Medar, Inc. Method and system for measuring color difference
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US6990458B2 (en) * 1997-08-28 2006-01-24 Csg Systems, Inc. System and method for computer-aided technician dispatch and communication
US6119124A (en) 1998-03-26 2000-09-12 Digital Equipment Corporation Method for clustering closely resembling data objects
US6240409B1 (en) 1998-07-31 2001-05-29 The Regents Of The University Of California Method and apparatus for detecting and summarizing document similarity within large document sets
DE69910140T2 (de) 1998-10-08 2004-06-03 Novartis Ag Verfahren zur Sulfurierung von Phosphor-enthaltenden Verbindungen
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7415313B2 (en) * 2000-07-07 2008-08-19 New Vectors Llc Spatial coordination system
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US6658423B1 (en) 2001-01-24 2003-12-02 Google, Inc. Detecting duplicate and near-duplicate files
WO2002067858A2 (en) * 2001-02-22 2002-09-06 University Of Maryland, Baltimore Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms
US6845394B2 (en) * 2001-04-16 2005-01-18 Sun Microsystems, Inc. Software delivery method with enhanced batch redistribution for use in a distributed computer network
AU2002305809B2 (en) 2001-06-08 2007-12-06 Ortho-Mcneil Pharmaceutical, Inc. Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
US20030008048A1 (en) 2001-06-08 2003-01-09 David Winston Methods and compositions for helping the body resist the effects of the aging process
WO2003082255A2 (en) * 2002-04-03 2003-10-09 Novartis Ag Use of mob-5 in pain
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
EP1592412A1 (en) * 2003-01-31 2005-11-09 Novartis AG Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
US20050132197A1 (en) 2003-05-15 2005-06-16 Art Medlar Method and apparatus for a character-based comparison of documents
US20070085716A1 (en) 2005-09-30 2007-04-19 International Business Machines Corporation System and method for detecting matches of small edit distance
US7499869B2 (en) * 2006-02-02 2009-03-03 Matthew Iknoian System and method for scheduling employee shifts
US7562186B2 (en) 2006-04-11 2009-07-14 Data Domain, Inc. Efficient data storage using resemblance of data segments

Also Published As

Publication number Publication date
WO2004022075A1 (en) 2004-03-18
EP1551424A1 (en) 2005-07-13
US20120053230A1 (en) 2012-03-01
US8129354B2 (en) 2012-03-06
US20060030534A1 (en) 2006-02-09
JP2006501256A (ja) 2006-01-12
JP4754216B2 (ja) 2011-08-24
US8198259B2 (en) 2012-06-12
JP2011178783A (ja) 2011-09-15
EP1551424B1 (en) 2015-07-01
US20080153768A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AU2003297761A1 (en) Methods for treating neurological language disorders
IL169091A0 (en) Benzazepine derivatives for the treatment of neurological disorders
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
AU2003258305A1 (en) Combination therapy for treatment of fibrotic disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
EP1617844A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
IL173351A0 (en) Therapy of ocular disorders
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
AU2003260489A1 (en) Treatment of neurological disorders by dsrna adminitration
AU2002229452A1 (en) Method of treating neurological disorders using acetone derivatives
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU2003239967A1 (en) Compound for the treatment of cns disorders
HK1085406A (en) Treatment of neurological conditions
AU2003254447A1 (en) Treatment of proliferative disorders
AU2004901652A0 (en) Treatment of neurological conditions
AU2002242293A1 (en) Treatment of neurological disease
AU2003244633A1 (en) Methods for the treatment of sinusitis
AU2002237894A1 (en) Methods of treating neurological disorders
AU2003900919A0 (en) Treatment of coronary disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase